Last reviewed · How we verify

KVA12123 Plus Pembrolizumab - Dose Expansion — Competitive Intelligence Brief

KVA12123 Plus Pembrolizumab - Dose Expansion (KVA12123 Plus Pembrolizumab - Dose Expansion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 1 Small molecule Live · refreshed every 30 min

Target snapshot

KVA12123 Plus Pembrolizumab - Dose Expansion (KVA12123 Plus Pembrolizumab - Dose Expansion) — Kineta Inc..

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
KVA12123 Plus Pembrolizumab - Dose Expansion TARGET KVA12123 Plus Pembrolizumab - Dose Expansion Kineta Inc. phase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KVA12123 Plus Pembrolizumab - Dose Expansion — Competitive Intelligence Brief. https://druglandscape.com/ci/kva12123-plus-pembrolizumab-dose-expansion. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: